Dermagraft, which is manufactured and marketed by Advanced BioHealing (ABH), is a human derived dermal substitute approved by the FDA for the treatment of diabetic foot ulcers (DFU). The pilot program, which will launch in Dallas and be tested in other US cities, will assist both patients and healthcare providers in addressing various issues that negatively impact patient compliance during their treatment for diabetic foot ulcers.
The goal of this pilot program is to determine whether a program can be developed that addresses some of the cultural and socioeconomic issues that tend to plague patients with active DFUs and improve the overall treatment outcome.
Sean Teare, president of InnovationRx, said: Our partnership with Advanced BioHealing is not only an industry first, but demonstrates the benefits of adherence services to pharmaceutical, medical device companies, health plans and pharmacies.
Any medical condition where patient adherence is an issue can benefit from personalized patient coaching, which in-turn can lead to improved disease management and medical outcomes.